The Scoliosis Research Society collaborated with the International Spine Study Group Foundation and several spine industry leaders to complete the Adult Symptomatic Lumbar Scoliosis II study.
Here are five things to know.
1. The corporate partners include:
- Globus Medical
- K2M
- Medtronic
- NuVasive
- Zimmer Biomet
2. The ASLS II study is continuation of the ASLS I study, a randomized, prospective NIH-funded study assessing the two-year outcomes of operative and nonoperative treatment for adult symptomatic lumbar scoliosis patients.
3. ASLS II will allow for eight-year follow-up of the 258 patients remaining from the ASLS I study. The study aims to evaluate:
- Long-term treatment outcomes and cost-effectiveness of operative versus non-operative treatment
- Optimal patient profiling for treatment efficacy
- Long-term functional assessment of patients using functional treadmill testing
- Treatment durability for operative and nonoperative treatment.
4. The study is underway at 10 centers in the U.S. and Canada. The ISSGF will act as the clinical research organization, providing a research platform for the study investigators for research organization, funding acquisition and distribution, in addition to study updates and data analysis.
5. The study is set to conclude in 2023.
More articles on spine:
Which factors impact rod slippage with magnetically controlled growing rods? 4 takeaways
Neurosurgeon Dr. Jim Maxwell begins campaign for New York representative seat: 5 takeaways
Toronto neurosurgeon to stand trial for the murder of physician wife